Biotechnology | Termination Agreements | Business Contracts

Termination and Settlement Agreement, dated December 22, 2022, by and between Keryx Biopharmaceuticals, Inc. and BioVectra Inc (Akebia Therapeutics, Inc., Filed With SEC on March 10, 2023)

Mutual Termination Agreement dated December 22, 2022, by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania (AMICUS THERAPEUTICS, INC., Filed With SEC on March 1, 2023)

Termination Agreement, dated February 7, 2023, by and between Oncocyte Corporation and Life Technologies Corporation (OncoCyte Corp, Filed With SEC on February 13, 2023)

Mutual Termination Agreement, dated December 12, 2022, by and between Exicure, Inc. and Ipsen Biopharm Limited (EXICURE, INC., Filed With SEC on December 14, 2022)

Termination of License Agreement, dated September 9, 2022, between Cue Biopharma, Inc. and MIL 21E, LLC (Cue Biopharma, Inc., Filed With SEC on November 14, 2022)

Termination Agreement and Release dated September 19, 2022 by and between iBio, Inc. and RubrYc Therapeutics, Inc (iBio, Inc., Filed With SEC on November 14, 2022)

Termination, Amendment and Program Transfer Agreement dated August 2, 2022, by and between Atara Biotherapeutics, Inc., and Bayer AG (Atara Biotherapeutics, Inc., Filed With SEC on November 8, 2022)

August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited (HEMISPHERX BIOPHARMA INC, Filed With SEC on August 15, 2022)

Termination Agreement between the Company and WuXi Biologics (Hong Kong) Limited dated May 16, 2022 (Vir Biotechnology, Inc., Filed With SEC on August 9, 2022)

Amendment No 1. to the Asset Return and Termination Agreement, by and between Baxalta Incorporated and CTI BioPharma Corp., dated as of May 31, 2022 (CTI BIOPHARMA CORP, Filed With SEC on August 8, 2022)

Termination and Settlement Agreement, dated (Akebia Therapeutics, Inc., Filed With SEC on August 4, 2022)

Revenue Interest Termination Agreement, dated June 7, 2022, by and between Spero Therapeutics, Inc., entities managed by HealthCare Royalty Management, LLC and HCR Collateral... (Spero Therapeutics, Inc., Filed With SEC on June 7, 2022)

Termination Agreement by and between Yumanity Therapeutics, Inc. and MIL 40, LLC dated as of February 28, 2022 (PROTEOSTASIS THERAPEUTICS, INC., Filed With SEC on March 4, 2022)

Notice of Termination of Sales Agreement between the Registrant and Cowen and Company, LLC, dated February 24, 2022 (Allakos Inc., Filed With SEC on March 1, 2022)

Termination Agreement between the Registrant and Lonza AG and affiliates thereof, dated February 14, 2022 (Allakos Inc., Filed With SEC on March 1, 2022)

Termination Agreement, dated as of February 23, 2022, by and between ARYA and the Company (AMICUS THERAPEUTICS, INC., Filed With SEC on February 24, 2022)

Mutual Termination, Release, and Settlement Agreement by and between G1 Therapeutics, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc., dated as of December 15, 2021 (G1 Therapeutics, Inc., Filed With SEC on February 23, 2022)

Termination Letter from Advaxis, Inc. to Biosight LTD., dated December 30, 2021 (Advaxis, Inc., Filed With SEC on December 30, 2021)

Takeda Termination Agreement (Shattuck Labs, Inc., Filed With SEC on November 9, 2021)

Mutual Termination Agreement, by and between Viracta Subsidiary, Inc. and Shenzhen Salubris Pharmaceutical Co. Ltd (SUNESIS PHARMACEUTICALS INC, Filed With SEC on August 23, 2021)

Letter dated June 22, 2021 to A.G.P./Alliance Global Partners giving notice of termination of Sales Agreement (RITTER PHARMACEUTICALS INC, Filed With SEC on August 16, 2021)

Termination Agreement, dated August 6, 2021, by and among Xenon Pharmaceuticals Inc., Genentech, Inc. and F. Hoffmann-La Roche Ltd (Xenon Pharmaceuticals Inc., Filed With SEC on August 11, 2021)

Termination and Modification Agreement, dated March 20, 2020, by and between the Registrant (formerly entered into by Fibrocell Science, Inc.) and Precigen, Inc (Castle Creek Biosciences, Inc., Filed With SEC on July 16, 2021)

Mutual Termination of the Scientific Advisory Board Agreement, dated March 17, 2018, by and between the Registrant and Jennifer A. Doudna (Caribou Biosciences, Inc., Filed With SEC on July 1, 2021)

Royalty, License and Termination Agreement, by and between the Company and Takeda Pharmaceutical Company Limited, dated March 2, 2021 (Ovid Therapeutics Inc., Filed With SEC on May 13, 2021)

Termination Agreement, dated February 24, 2021, by and between the Company and CANbridge BIOMED Limited (PUMA BIOTECHNOLOGY, INC., Filed With SEC on May 6, 2021)

Termination Agreement between the Registrant, The Henry M. Jackson Foundation, and the MD Anderson Cancer Center, dated February 4, 2021 (SELLAS Life Sciences Group, Inc., Filed With SEC on March 23, 2021)

Amendment and Termination Agreement (PREDICTIVE TECHNOLOGY GROUP, INC., Filed With SEC on January 19, 2021)

Cashless Exercise Notice, Amendment, Waiver, Release and Termination, dated December 14, 2020, by and among Anchiano Therapeutics Ltd., Shavit Capital Fund III (US), L.P., Shavit... (Anchiano Therapeutics Ltd., Filed With SEC on December 15, 2020)

Termination and Release Agreement dated September 29, 2020, by and between Catalent Belgium S.A. and Palatin Technologies, Inc (PALATIN TECHNOLOGIES INC, Filed With SEC on November 16, 2020)

Termination of Exclusive License Agreement, effective November 9, 2020, by and among Cedars- Sinai Medical Center, Synthetic Biologics, Inc. and Synthetic Biomics, Inc (Synthetic Biologics, Inc., Filed With SEC on November 10, 2020)

Termination Agreement, dated August 5, 2020, by and between the Company and Allergan Sales, LLC (Editas Medicine, Inc., Filed With SEC on November 6, 2020)

Termination Agreement (Inspyr Therapeutics, Inc., Filed With SEC on October 8, 2020)

Termination Agreement by and among the Company, SpePharm and Norgine (NAVIDEA BIOPHARMACEUTICALS, INC., Filed With SEC on May 12, 2020)

Termination Agreement between Andrea van Elsas and Aduro Biotech, Inc. dated April 10, 2020 (ADURO BIOTECH, INC., Filed With SEC on May 4, 2020)

Conversion, Termination and Release Agreement, dated August 10, 2016, by and among Histogen Inc., Jonathan Jackson, Lordship Ventures LLC and Lordship Ventures Histogen Holdings... (Conatus Pharmaceuticals Inc., Filed With SEC on February 7, 2020)

Settlement, Release and Termination Agreement, dated April 5, 2019, by and among Histogen Inc., PUR Biologics, LLC, Wylde, LLC, Christopher Wiggins and Ryan Fernan (Conatus Pharmaceuticals Inc., Filed With SEC on February 7, 2020)

Termination of Stockholder Agreements, dated January 28, 2020, by and among Histogen Inc., Lordship Ventures Histogen Holdings LLC, Pineworld Capital Limited, Gail K. Naughton,... (Conatus Pharmaceuticals Inc., Filed With SEC on February 7, 2020)

Termination Agreement and Mutual Release between the Company and MTTR LLC, dated as of January 27, 2020 (Outlook Therapeutics, Inc., Filed With SEC on January 31, 2020)

Termination Agreement, dated December 27, 2019, by and between CRISPR Therapeutics AG and Rodger Novak (CRISPR Therapeutics AG, Filed With SEC on December 27, 2019)

Biotechnology (54) | Termination Agreements (54)